Earnings ·
Alto Neuroscience reports Q3 net loss of $25.1M and extends cash runway to 2030 with $319.8M balance sheet
ANROAlto Neuroscience, Inc.
Alto Neuroscience reported a net loss of $25.1 million for the quarter ended September 30, 2026, compared to a $14.2 million loss in the prior-year period. Research and development expenses rose to $18.2 million from $10.5 million, driven by costs associated with the ALTO-207 PACE program, while general and administrative expenses increased to $9.1 million from $4.4 million due to higher headcount. The company ended the quarter with $319.8 million in cash, cash equivalents, and restricted cash, up from $177.0 million at year-end 2025, providing a runway through 2030. Clinical updates include PACE-1 trial enrollment on track for topline data in late 2027 and Phase 3 planning for ALTO-207. Alto Neuroscience is a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders.